Diffuse large B-cell lymphoma is a cancer of mature
B-lymphocytes. It is a form of non-Hodgkin
lymphoma, which is a type of cancer that originates in cells of the immune
system, called lymphocytes.
Diffuse large B-cell lymphoma is more common in adults than
in children, and behaves differently in adults than in children. In children
and adolescents, diffuse large B-cell lymphoma is usually treated in the same
way that Burkitt
lymphoma is treated. Although diffuse large B-cell lymphoma is an
aggressive cancer, it is not as fast growing as Burkitt lymphoma.
Children with non-Hodgkin lymphoma are treated at
Dana-Farber/Boston Children's through the Lymphoma
Program in our Hematologic Malignancies Center.
One of the top pediatric cancer centers worldwide, Dana-Farber/Boston
Children’s combines the expertise of a premier cancer center – Dana-Farber
Cancer Institute – and a world-class children’s hospital – Boston Children’s
Hospital – to provide internationally-renowned care for children with cancers
of the blood and immune system.
For the purpose of deciding how much treatment is necessary,
diffuse large B-cell lymphoma may be divided by stage (localized or advanced)
or by the risk group classification that is used for Burkitt Lymphoma.
The lymphoma specialists at Dana-Farber/Boston Children’s
determine the best approach to treatment for each child's unique situation,
based on the type of lymphoma, the extent of the disease, the patient’s medical
condition, the patient and family’s preferences, and the most up-to-date
medical knowledge about lymphoma therapies.
Newly diagnosed, localized, diffuse large B-cell lymphoma, may
be treated with a short 9-week course of chemotherapy, including the drugs
cyclophosphamide, doxorubicin, vincristine and prednisone.
If your child has advanced diffuse large B-cell lymphoma,
treatment is the same as the treatment for Burkitt Lymphoma.
Sometimes older adolescents may be treated with the same
chemotherapy regimen that is used for adult diffuse large B-cell lymphoma. This
treatment program is called “R-CHOP”.
The cure rate for diffuse large B-cell lymphoma is very
refractory diffuse large B-cell lymphoma
For diffuse large B-cell lymphoma that does not respond to
initial treatment (refractory) or that comes back after treatment (relapse), treatment
recommendations are the same as for relapsed or refractory Burkitt Lymphoma.
more about non-Hodgkin lymphoma, including:
Phone: 617-632-5508Online form: Request an appointment
U.S. News & World Report ranked Dana-Farber/Boston Children's the #1 pediatric cancer hospital in the nation.